EA
UTHR icon

Evanston Advisors’s United Therapeutics UTHR Stock Holding History

Evanston Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-68,193
Closed -$7.72M – 78
2018
Q2 		$7.72M Buy
68,193
+6,984
+11% +$768K 1.74% 32
2018
Q1 		$6.88M Buy
61,209
+2,010
+3% +$255K 1.6% 35
2017
Q4 		$8.76M Buy
59,199
+2,875
+5% +$365K 2.1% 16
2017
Q3 		$6.6M Buy
56,324
+1,041
+2% +$133K 1.59% 35
2017
Q2 		$7.17M Buy
55,283
+8,426
+18% +$1.05M 1.76% 31
2017
Q1 		$6.34M Sell
46,857
-4,381
-9% -$664K 1.72% 36
2016
Q4 		$7.35M Sell
51,238
-682
-1% -$87.1K 2.26% 15
2016
Q3 		$6.13M Buy
51,920
+1,882
+4% +$226K 1.92% 27
2016
Q2 		$5.3M Buy
50,038
+4,880
+11% +$544K 1.73% 31
2016
Q1 		$5.03M Buy
+45,158
New +$5.71M 1.66% 36
2015
Q2 		– Sell
-39,619
Closed -$6.83M – 66
2015
Q1 		$6.83M Sell
39,619
-2,354
-6% -$359K 2.24% 7
2014
Q4 		$5.43M Buy
41,973
+121
+0.3% +$15.6K 1.92% 30
2014
Q3 		$5.38M Sell
41,852
-14,886
-26% -$1.53M 1.82% 28
2014
Q2 		$5.02M Buy
+56,738
New +$5.46M 1.74% 34

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Evanston Advisors's UTHR Position: Q3 2018 in Review

Evanston Advisors sold out of United Therapeutics (UTHR) in Q3 2018, closing a stake of 68,193 shares — an estimated $7.72M sold.

Evanston Advisors first reported a position in UTHR in Q2 2014 and held it in 14 quarters. The position peaked at $8.76M in Q4 2017. 367 funds tracked by Wall St. Rank hold UTHR as of Q3 2018.

  • Evanston Advisors reported no remaining United Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Evanston Advisors sold 68,193 United Therapeutics shares in Q3 2018, an estimated $7.72M.
  • Evanston Advisors first reported a position in United Therapeutics in Q2 2014 and held it in 14 quarters.
  • Evanston Advisors's United Therapeutics position peaked at $8.76M in Q4 2017.
  • 367 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2018.

Based on Evanston Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.